Amisulpride

Drug Profile

Amisulpride

Alternative Names: Aminosultopride; Amitrex; DAN 2163; Deniban; Enorden; Socian; Solian; Sulamid

Latest Information Update: 13 Oct 2011

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antidepressants; Antiemetics; Antipsychotics; Benzamides; Pyrrolidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dysthymic disorder; Major depressive disorder; Schizophrenia

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 04 Feb 2003 A study has been added to the Psychotic disorders therapeutic trials section
  • 27 Aug 2002 Launched for Dysthymic disorder in Greece (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top